BloodNotes

Staying Connected. Keeping you informed.

Discontinuation of apheresis fresh frozen plasma 500 ml

In September 2021, Canadian Blood Services issued a customer letter (CL2021-37) informing hospitals that the production of apheresis fresh frozen plasma (AFFP) sodium citrate – 500 ml with product code E0909V00 would be discontinued in February 2022. We advise hospitals to watch for future customer letters as this target date could change.

Canadian Blood Services has seen the distribution of AFFP 500 ml decline year over year; that's why the organization decided to discontinue the production of AFFP 500 ml and instead increase the amount of Canadian plasma sent for fractionation into immunoglobulin.

In clinical cases where plasma components are indicated, frozen plasma (whole blood-derived), AFFP ACD-A 250 mL, and apheresis frozen plasma ACD-A 250 mL can be used interchangeably instead of AFFP 500mL.

Hospitals need to be aware of the following changes:

- By February 2022, collection and manufacturing of AFFP sodium citrate – 500 ml with product code E090V00, will be discontinued.
- In no later than one year, AFFP sodium citrate – 500 ml with product code E090V00 will be delisted from Canadian Blood Services' product portfolio.
- The *Circular of Information, Plasma Components (AFFP, FP CPD, Cryosupernatant CPD, Cryoprecipitate CDP)* will be updated later to reflect changes when the AFFP sodium citrate – 500 ml is removed from Canadian Blood Services' product portfolio.

Hospitals are advised not to remove the code for AFFP sodium citrate – 500 ml from their laboratory information systems until they are notified through a customer letter to do so. The product may be distributed to hospitals for up to one year after it is discontinued due to existing inventory.

To read more articles, please visit the BloodNotes section of blood.ca